GRIT Biotechnology
GRIT disclosed T-cell-targeted mRNA/LNP GT801 and a separate lentiviral direction. GT801 is also developed through spinout Vivacta Bio; the two company profiles describe a shared program lineage, not two independent drugs. GRIT’s TIL clinical stages are separate.
Corporate information
- Company entity
- GRIT Biotechnology
- Headquarters / principal office
- Beijing relocation in 2025; public contact address remains in Shanghai ↗
- Founded
- 2019 ↗
- Ownership / capital status
- PrivateSeries B+ (2024 historical disclosure) ↗
- Official corporate reference
- https://www.grit-bio.com/vivo-cart ↗
- Latest financing / award identified
- 2024 · Series B+ · Undisclosed ↗
- LinkedIn company page
- Independent company page not verified
Company history gives the year and round, without an exact amount.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
GRIT disclosed T-cell-targeted mRNA/LNP GT801 and a separate lentiviral direction. GT801 is also developed through spinout Vivacta Bio; the two company profiles describe a shared program lineage, not two independent drugs. GRIT’s TIL clinical stages are separate.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- GRIT Biotechnology — primary program / ownership disclosure
- GRIT Biotechnology — supporting primary disclosure
- Corporate ownership / financing disclosure